"The TriHealth Cancer Institute wields the power of the full TriHealth system, which has been named among the country's Top 100 Most Integrated Health Networks 13 times. From outcomes, to prudent management of resources, to caring and compassionate service, to innovative research, TriHealth operates in an environment of continuous quality improvement across its more than 80 locations. As the landscape of health care continues to evolve both nationally and locally, TriHealth is prepared to respond to the demand for more coordinated, patient-centered models of care with strong physician collaboration and leadership."

During the past decade, TriHealth Cancer Institute-Westside conducted 148 clinical trials. In the 10-year time frame, 148 clinical trials started and 53 clinical trials were completed, i.e. on average, 35.8% percent of trials that started reached the finish line to date. In the past 5 years, 63 clinical trials started and 49 clinical trials were completed. i.e. 77.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "TriHealth Cancer Institute-Westside" #1 sponsor was "National Cancer Institute (NCI)" with 79 trials, followed by "SWOG Cancer Research Network" with 29 trials sponsored, "Alliance for Clinical Trials in Oncology" with 21 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 16 trials sponsored and "NRG Oncology" with 16 trials sponsored. Other sponsors include 21 different institutions and companies that sponsored additional 21 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "TriHealth Cancer Institute-Westside" #1 collaborator was "National Cancer Institute (NCI)" with 83 trials as a collaborator, "NRG Oncology" with 19 trials as a collaborator, "Canadian Cancer Trials Group" with 6 trials as a collaborator, "AstraZeneca" with 3 trials as a collaborator and "Genentech, Inc." with 2 trials as a collaborator. Other collaborators include 20 different institutions and companies that were collaborators in the rest 30 trials.

According to Clinical.Site data, the most researched conditions in "TriHealth Cancer Institute-Westside" are "Recurrent Ovarian Carcinoma" (9 trials), "Recurrent Squamous Cell Lung Carcinoma" (8 trials), "Stage IV Lung Cancer AJCC v8" (7 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (7 trials) and "Breast Cancer" (6 trials). Many other conditions were trialed in "TriHealth Cancer Institute-Westside" in a lesser frequency.

Most popular intervention types in "TriHealth Cancer Institute-Westside" are "Drug" (135 trials), "Other" (108 trials), "Biological" (75 trials), "Procedure" (50 trials) and "Radiation" (12 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (49 trials), "Quality-of-Life Assessment" (38 trials), "Computed Tomography" (28 trials), "Biospecimen Collection" (26 trials) and "Nivolumab" (26 trials). Other intervention names were less common.

The vast majority of trials in "TriHealth Cancer Institute-Westside" are 143 trials for "All" genders, 32 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "TriHealth Cancer Institute-Westside". undefined are not yet recruiting, 62 are recruiting, 80 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 27 completed trials in TriHealth Cancer Institute-Westside, 1 suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in TriHealth Cancer Institute-Westside, 4 "Phase 1" clinical trials were conducted, 85 "Phase 2" clinical trials and 81 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 6 trials that are defined as “Not Applicable".